Taysha Gene Therapies Inc
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
TSHA$4.37+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ (Deficit) Equity
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
(in thousands, except share data)
For the Three Months Ended March 31, 2025
| Additional | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Accumulated Other · Total | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Stockholders' Equity | |
| Balance as of December 31, 2024 | 204,943,306 | $2 | $677,859 | $(602,305) | $(4,031) | $71,525 |
| Stock-based compensation | — | — | 3,294 | — | — | 3,294 |
| Issuance of common stock upon vesting and settlement of restricted stock units, net | 52,938 | — | (51) | — | — | (51) |
| Issuance of common stock under ESPP | 58,326 | — | 75 | — | — | 75 |
| Gain on instrument-specific credit risk | — | — | — | — | 1,745 | 1,745 |
| Net loss | — | — | — | (21,529) | — | (21,529) |
| Balance as of March 31, 2025 | 205,054,570 | $2 | $681,177 | $(623,834) | $(2,286) | $55,059 |
For the Three Months Ended March 31, 2024
| Additional · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Accumulated Other · Stockholders' | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Equity (Deficit) | |
| Balance as of December 31, 2023 | 186,960,193 | $2 | $587,942 | $(513,007) | $— | $74,937 |
| Stock-based compensation | — | — | 3,198 | — | — | 3,198 |
| Issuance of common stock upon vesting and settlement of restricted stock units, net | 11,282 | — | — | — | — | — |
| Issuance of common stock under ESPP | 46,800 | — | 26 | — | — | 26 |
| Loss on instrument-specific credit risk | — | — | — | — | (251) | (251) |
| Net loss | — | — | — | (24,061) | — | (24,061) |
| Balance as of March 31, 2024 | 187,018,275 | $2 | $591,166 | $(537,068) | $(251) | $53,849 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.